{
  "meta": {
    "title": "100_Hiv_Aids_-_Management_And_Prophylaxis",
    "url": "https://brainandscalpel.vercel.app/100-hiv-aids-management-and-prophylaxis-60f9d2c0.html",
    "scrapedAt": "2025-11-30T12:28:20.707Z"
  },
  "questions": [
    {
      "text": "Anti-retroviral therapy in HIV-infected individuals should be initiated at _______",
      "choices": [
        {
          "id": 1,
          "text": "CD4 count <200 cells/ul and/or WHO clinical stage 2/3"
        },
        {
          "id": 2,
          "text": "CD4 count <350 cells/ul and/or WHO clinical stage 3/4"
        },
        {
          "id": 3,
          "text": "CD4 count <250 cells/ul and/or WHO clinical stage 4"
        },
        {
          "id": 4,
          "text": "Any CD4 count regardless of WHO clinical stage"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Antiretroviral therapy (ART) is recommended for <strong>all</strong><strong>&nbsp;HIV patients, regardless of CD4</strong> <strong>T lymphocyte cell count</strong> or clinical stage.</p>\n<p>This is done to reduce the morbidity and mortality associated with HIV infection. A secondary goal of ART is to reduce the risk of HIV transmission.</p><p><strong>Islatravir,</strong> the first nucleoside reverse transcriptase translocation inhibitor <strong>(NRTTI),</strong> along with <strong>Doravirine</strong> the recently approved non-nucleoside reverse transcriptase inhibitor <strong>(NNRTI)</strong> may offer a potent and well-tolerated two-drug regimen for HIV maintenance therapy, according to a recent study.</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2150",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is true about fourth-generation serological testing for HIV?",
      "choices": [
        {
          "id": 1,
          "text": "It is used to confirm the diagnosis of HIV"
        },
        {
          "id": 2,
          "text": "It detects HIV antibodies and antigen"
        },
        {
          "id": 3,
          "text": "It has a lower sensitivity compared to first-generation HIV testing"
        },
        {
          "id": 4,
          "text": "It cannot be used to detect HIV-2 antibodies"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The 4<sup>th&nbsp;</sup>generation HIV test combines the detection of <strong>antibodies against HIV-1 &amp; HIV-2</strong> with detection of the <strong>core p24 antigen</strong> <strong>of HIV-1</strong>. Inclusion of p24 antigen capture allows detection of <strong>HIV-1 infection</strong>&nbsp;even before seroconversion i.e., presence of antibodies in the blood.</p>\n<p>The approximate time to positivity following infection is 15 to 20 days. Consequently, the window period between infection and detection of the infection is shortened.</p>\n<p>Fourth-generation HIV testing is <strong>highly sensitive (99.9%)&nbsp;</strong>and is the CDC-recommended initial screening test for HIV. <strong>No further testing</strong> is required for specimens that are non-reactive on ELISA screening.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Generation</strong></td>\n<td><strong>Serological test</strong></td>\n</tr>\n<tr>\n<td>First generation</td>\n<td>IgG antibody</td>\n</tr>\n<tr>\n<td>Second generation</td>\n<td>IgG antibody</td>\n</tr>\n<tr>\n<td>Third generation</td>\n<td>IgM and IgG antibody</td>\n</tr>\n<tr>\n<td>Fourth generation</td>\n<td>IgM and IgG antibody and p24 antigen</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2148",
      "difficulty": "medium"
    },
    {
      "text": "A 46-year-old man, who is a chronic alcoholic, presented with acute dull and boring abdominal pain. His history is significant for ongoing treatment with ART. Serum lipase levels were noted to be grossly elevated. What is the most likely causative drug?",
      "choices": [
        {
          "id": 1,
          "text": "Nevirapine"
        },
        {
          "id": 2,
          "text": "Didanosine"
        },
        {
          "id": 3,
          "text": "Emtricitabine"
        },
        {
          "id": 4,
          "text": "Stavudine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Didanosine</strong> is the most likely causative drug. The clinical scenario, suggestive of <strong>pancreatitis,</strong> is a dose-limiting<strong> side effect</strong> of <strong>didanosine</strong> and occurs more frequently in alcoholic patients and those with hypertriglyceridemia.</p>\n<p>Option A:<strong>&nbsp;Nevirapine</strong> side-effects include severe liver problems, skin rash, and skin reactions.&nbsp;</p>\n<p>Option C: <strong>Emtricitabine</strong>&nbsp;is contraindicated in pregnancy and young children.</p>\n<p>Option D: <strong>Stavudine</strong>&nbsp;can cause peripheral neuropathy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2151",
      "difficulty": "medium"
    },
    {
      "text": "An HIV-positive patient is upset because he has a high viral load despite good compliance with ART. The physician decides to start him on a parenteral drug. Which of the following drugs will be helpful for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Emtricitabine"
        },
        {
          "id": 2,
          "text": "Elvitegravir"
        },
        {
          "id": 3,
          "text": "Enfuvirtide"
        },
        {
          "id": 4,
          "text": "Efavirenz"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Enfuvirtide</strong> is the antiretroviral drug administered <strong>parenterally,&nbsp;</strong>used only in the treatment of those who have evidence of HIV replication&nbsp;i.e., <strong>high</strong> <strong>viral load</strong>, despite ongoing antiretroviral therapy.&nbsp;</p>\n<p>Enfuvirtide <strong>prevents viral fusion </strong>and entry by binding to the gp41 subunit of the HIV-1 envelope. It is <strong>not active against HIV-2.</strong> It is administered as a twice-a-day <strong>subcutaneous </strong>injection.</p>\n<p>Note:&nbsp;<strong>Zidovudine</strong> is also available as a parenteral formulation.</p><p>The FDA has recently approved a combination of <strong>cabotegravir and rilpivirine&nbsp;</strong>as a complete regimen for <strong>HIV-1 infected adults. </strong>It was introduced to replace the current regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the <strong>first FDA-approved</strong> <strong>injectable</strong>&nbsp;<strong>regimen</strong> for HIV-1 infected adults.</p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2152",
      "difficulty": "medium"
    },
    {
      "text": "An HIV-positive patient has the following serology results. What is the management of this patient?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Markers</strong></p>\n</td>\n<td><strong>Result</strong></td>\n</tr>\n<tr>\n<td>HBsAg</td>\n<td>Positive</td>\n</tr>\n<tr>\n<td>anti-HBc</td>\n<td>Positive</td>\n</tr>\n<tr>\n<td>IgM anti-HBc</td>\n<td>Positive</td>\n</tr>\n<tr>\n<td>anti-HBs</td>\n<td>Negative</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir + emtricitabine + abacavir"
        },
        {
          "id": 2,
          "text": "Tenofovir + lamivudine + dolutegravir"
        },
        {
          "id": 3,
          "text": "Lamivudine + emtricitabine + nevirapine"
        },
        {
          "id": 4,
          "text": "Tenofovir + lamivudine + efavirenz"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;an <strong>acute infection</strong> with <strong>hepatitis B</strong> virus. The preferred regimen in the management of HIV-1 and hepatitis B <strong>co-infection</strong> is <strong>tenofovir + lamivudine + dolutegravir.&nbsp;</strong></p>\n<p class=\"p1\">This regimen is also the first-line management in adults, adolescents, pregnant women, and&nbsp;HIV-TB co-infection.&nbsp;</p>\n<p>Antivirals that are effective against <strong>hepatitis C</strong> infection are&nbsp;<strong>sofosbuvir, grazoprevir</strong>&nbsp;and<strong> glecaprevir</strong>.</p>\n<p>*Note: Pearl attached below has been updated according to the NACO ART guidelines 2021. Efavirenz has been replaced by <strong>Dolutegravir</strong> as per the new guidelines.</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME9416",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following antiretroviral drugs is not used in HIV & hepatitis B co-infection?",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir"
        },
        {
          "id": 2,
          "text": "Abacavir"
        },
        {
          "id": 3,
          "text": "Lamivudine"
        },
        {
          "id": 4,
          "text": "Emtricitabine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Abacavir</strong> is <strong>not used</strong> in <strong>HIV and hepatitis-B co-infection</strong>. It is used in the <strong>first-line ART regimen</strong> for patients with <strong>abnormal serum creatinine</strong> values.</p>\n<p>Nucleoside reverse transcriptase inhibitor (NRTI) drugs like&nbsp;<strong>lamivudine,</strong>&nbsp;its closely related drug <strong>emtricitabine,</strong> and the nucleotide reverse transcriptase inhibitor (NRTI) <strong>t</strong><strong>enofovir</strong>&nbsp;have activity <strong>against hepatitis B virus</strong>.&nbsp;These drugs are preferred in combination with other antiretrovirals for the treatment of HIV &amp; HBV co-infections.</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2153",
      "difficulty": "medium"
    },
    {
      "text": "Screening of patients for HLA- B5701 is recommended before initiation of which of the following antiretroviral drugs?",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir"
        },
        {
          "id": 2,
          "text": "Abacavir"
        },
        {
          "id": 3,
          "text": "Zidovudine"
        },
        {
          "id": 4,
          "text": "Emtricitabine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Screening of patients for <strong>HLA-B5701</strong> is recommended before initiation of <strong>abacavir </strong>since it&nbsp;is associated with <strong>hypersensitivity.</strong></p>\n<p>The&nbsp;hypersensitivity syndrome includes&nbsp;fever, maculopapular rash, abdominal pain, gastrointestinal problems, malaise and fatigue. Hence, abacavir should only be used as a last resort and with close monitoring in patients who are HLA-B5701-positive.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2154",
      "difficulty": "medium"
    },
    {
      "text": "Evaluation of a patient with uncontrolled type 2 diabetes mellitus and hypertension has revealed moderately increased albuminuria. He has recently been diagnosed with HIV infection. Combination ART preparations including which of the following drugs should be avoided?",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir"
        },
        {
          "id": 2,
          "text": "Lamivudine"
        },
        {
          "id": 3,
          "text": "Emtricitabine"
        },
        {
          "id": 4,
          "text": "Dolutegravir"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenerio is suggestive of early stages of diabetic and hypertensive kidney disease. So combinaton antiretroviral therapy (cART) preparations including <strong>tenfovir should not</strong> be prescribed to this patient.</p>\n<p><strong>Tenofovir</strong> is primarily eliminated by the kidneys and&nbsp;is<strong> contraindicated </strong>in patients with<strong> renal impairment</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2155",
      "difficulty": "hard"
    },
    {
      "text": "A 36-year-old HIV-positive man on cART is presented with the following finding. What is the most likely cause?",
      "choices": [
        {
          "id": 1,
          "text": "Abacavir"
        },
        {
          "id": 2,
          "text": "Entecavir"
        },
        {
          "id": 3,
          "text": "Nelfinavir"
        },
        {
          "id": 4,
          "text": "Adefovir"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;<strong>fat redistribution</strong> resulting in the classic <strong>buffalo hump</strong> appearance.&nbsp;<strong>Nelfinavir</strong> is the most likely cause.</p>\n<p class=\"p1\">It&nbsp;is a protease inhibitor and its&nbsp;<strong>chronic administration </strong>can result in fat redistribution and<strong>&nbsp;metabolic syndrome.&nbsp;</strong></p>\n<p class=\"p1\">Note: <strong>Atazanavir</strong> has the least propensity to cause lipodystrophy and metabolic syndrome.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/6b659a4efa4d47d493572689970cb6ed.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2159",
      "difficulty": "medium"
    },
    {
      "text": "A 54-year-old HIV-positive woman has a Hb of 8gm/dl. Combination ART preparations including which of the following drugs should be avoided?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine"
        },
        {
          "id": 2,
          "text": "Tenofovir"
        },
        {
          "id": 3,
          "text": "Raltegravir"
        },
        {
          "id": 4,
          "text": "Emtricitabine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Zidovudine</strong> should be avoided in this patient because the primary toxicity of zidovudine is <strong>bone marrow suppression.&nbsp;</strong>It can lead to anemia and neutropenia, which may require transfusions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2156",
      "difficulty": "medium"
    },
    {
      "text": "During his routine counselling, a war veteran on cART for the past 2 weeks tells his therapist that he wishes to discontinue his HIV treatment. He explains that since starting them, he has been having extreme dizziness and intense nightmares leading to repeated wakening in the night. What is the likely cause?",
      "choices": [
        {
          "id": 1,
          "text": "Tenofovir"
        },
        {
          "id": 2,
          "text": "Dolutegravir"
        },
        {
          "id": 3,
          "text": "Efavirenz"
        },
        {
          "id": 4,
          "text": "Lamivudine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The patient is most likely prescribed a cART regimen including <strong>efavirenz</strong>.</p>\n<p>Many patients treated with <strong>efavirenz</strong> note a feeling of light-headedness and <strong>dizziness</strong> following the initiation of therapy. They also complain of <strong>insomnia</strong>, <strong>vivid dreams</strong> and <strong>nightmares</strong>.</p>\n<p>These symptoms are self-limiting and tend to <strong>disappear&nbsp;gradually</strong> after several weeks of therapy. If the&nbsp;sleep problems are persistent, stopping the drug is the only solution.</p>\n<p>It is recommended to take efavirenz before bedtime to minimize side effects.</p>\n<p>The CNS/ <strong>psychiatric adverse effects</strong> seen with the use of <strong>efavirenz</strong> are:</p>\n<ul>\n<li>Frank psychosis (depression, hallucinations, and/or mania)&nbsp;</li>\n<li>Impaired concentration</li>\n<li>Dysphoria&nbsp;</li>\n<li>Dizziness</li>\n<li>Vivid dreams</li>\n<li>Insomnia</li>\n</ul>\n<p>*Note: Pearl attached below has been updated according to the NACO ART guidelines 2021. Efavirenz has been replaced by <strong>Dolutegravir</strong> as per the new guidelines.</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2158",
      "difficulty": "medium"
    },
    {
      "text": "A 38-year-old man is tested for HIV and the following band pattern is seen on a standard western blot. Protein gp36 is present on the immunoblotting assay. To which class of antiretroviral drug would he be intrinsically resistant?<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>Env</strong> (gp160, gp120,gp41)</td>\n<td><strong>&nbsp;Negative</strong></td>\n</tr>\n<tr>\n<td><strong>Gag</strong> (p55, p24, p17)</td>\n<td><strong>&nbsp;Positive</strong></td>\n</tr>\n<tr>\n<td><strong>Pol</strong> (p66, p51, p32)</td>\n<td><strong>&nbsp;Positive</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "Nucleoside reverse transcriptase inhibitors"
        },
        {
          "id": 2,
          "text": "Nucleotide reverse transcriptase inhibitors"
        },
        {
          "id": 3,
          "text": "Non-nucleoside reverse transcriptase inhibitors"
        },
        {
          "id": 4,
          "text": "Integrase strand transfer inhibitors"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of&nbsp;<strong>HIV-2</strong>&nbsp;infection. It<strong>&nbsp;</strong>is <strong>intrinsically resistant</strong>&nbsp;to non-nucleoside reverse transcriptase inhibitors (<strong>NNRTI</strong>)&nbsp;and also to fusion inhibitor <strong>enfuvirtide</strong><strong>.&nbsp;</strong></p>\n<p class=\"p1\">Western blot has a <strong>high specificity.&nbsp;</strong>It detects specific antibodies against multiple proteins of all 3 major HIV genes - <strong><em>gag, pol, </em></strong>and<strong><em> env</em></strong>.&nbsp;</p>\n<p class=\"p1\">Persons with <strong>HIV-2</strong> will often have an <strong>indeterminate western blot pattern</strong>&nbsp;showing the presence of Gag bands and Pol bands, but an <strong>absence of Env bands</strong>. This pattern occurs because HIV-1 and HIV-2 share little similarity in the&nbsp;<strong><em>env</em>&nbsp;gene</strong>.&nbsp;Moreover, the presence of <strong>gp36</strong>&nbsp;points towards a diagnosis of<strong>&nbsp;</strong>HIV-2.</p>\n<p>In India, NACO provides western blot confirmatory testing <strong>only to resolve indeterminate results</strong> on previous serological testing and <strong>not</strong> for <strong>routine confirmation</strong> after a&nbsp;positive result on screening tests.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2162",
      "difficulty": "medium"
    },
    {
      "text": "An individual positive for HIV-1 infection was started on a combination ART regimen of tenofovir–emtricitabine–efavirenz. After 6 months, failure of treatment was established and attributed to efavirenz resistance. Which drug of the same class can be used instead?",
      "choices": [
        {
          "id": 1,
          "text": "Delavirdine"
        },
        {
          "id": 2,
          "text": "Nevirapine"
        },
        {
          "id": 3,
          "text": "Nelfinavir"
        },
        {
          "id": 4,
          "text": "Etravirine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Etravirine</strong> can be used instead of efavirenz.</p>\n<p><strong>Etravirine</strong> is a non-nucleoside reverse transcriptase inhibitor <strong>(NNRTI)</strong> currently approved for the treatment of HIV infection in combination with other agents in <strong>treatment-experienced patients.</strong></p>\n<p>Options A, B: Etravirine is active against strains of HIV that are resistant to other NNRTIs such as&nbsp;<strong>delavirdine</strong>, <strong>nevirapine,</strong> and&nbsp;<strong>efavirenz</strong> which all exhibit <strong>cross-resistance</strong>. Rilpivirine, an NNRTI, is also effective across a broad range of NNRTI-resistant viruses but shares cross-resistance with etravirine.</p>\n<p>Option C: <strong>Nelfinavir</strong> is a protease inhibitor and hence, does not belong to the same class.</p><hr><h3>Related Pearl: Classification of antiretroviral drugs</h3><table>\n<tbody>\n<tr>\n<td><strong>CLASS</strong></td>\n<td><strong>DRUGS</strong></td>\n</tr>\n<tr>\n<td>Nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Zidovudine, Stavudine, Lamivudine, Abacavir, Emtricitabine, Didanosine</td>\n</tr>\n<tr>\n<td>Nucleotide Reverse Transcriptase Inhibitors</td>\n<td>Tenofovir</td>\n</tr>\n<tr>\n<td>Non-nucleoside Reverse Transcriptase Inhibitors</td>\n<td>Nevirapine, Efavirenz, Delavirdine,&nbsp;Etravirine</td>\n</tr>\n<tr>\n<td>Protease Inhibitors</td>\n<td>Saquinavir, Indinavir, Ritonavir, Nelfinavir, Lopinavir, Atazanavir, Tiprinavir, Darunavir</td>\n</tr>\n<tr>\n<td>Entry Inhibitors</td>\n<td>Enfuvirtide, Maraviroc</td>\n</tr>\n<tr>\n<td>Integrase Inhibitors</td>\n<td>Raltegravir, Elvitegravir, Dolutegravir</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p class=\"p1\">&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2157",
      "difficulty": "hard"
    },
    {
      "text": "A woman is diagnosed to be positive for HIV in her first trimester. What is the appropriate management?",
      "choices": [
        {
          "id": 1,
          "text": "Start ART immediately and continue till 6 weeks after delivery"
        },
        {
          "id": 2,
          "text": "Start ART after 1st trimester and continue life-long"
        },
        {
          "id": 3,
          "text": "Start ART immediately and continue life-long"
        },
        {
          "id": 4,
          "text": "Start ART after 1st trimester and continue till 6 weeks after delivery"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>ART</strong> should be <strong>initiated immediately and&nbsp;continued lifelong</strong> in<strong>&nbsp;</strong>all <strong>pregnant </strong>and<strong> breastfeeding </strong>women with <strong>HIV. </strong>This is&nbsp;regardless of their WHO clinical stage and CD4 cell count.</p>\n<p>*Note: Pearl attached below has been updated according to the NACO ART guidelines 2021. Efavirenz has been replaced by <strong>Dolutegravir</strong> as per the new guidelines.</p><hr><h3>Related Pearl: NACO ART Guidelines- 2021</h3><table class=\"t1\">\n<tbody>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">ART regimen</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">First-line for:</p>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Dolutegravir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>All PLHIV who are<strong> age &gt;10 years and body weight &gt;30 kg&nbsp;</strong>with <strong>HIV-1, HIV-2, HIV 1&amp;2 co-infection</strong>&nbsp;who have not received any ART&nbsp;</li>\n<li aria-level=\"1\">Those with <strong>HIV-TB and HIV hepatitis co-infections</strong></li>\n<li aria-level=\"1\"><strong>Pregnant women</strong>, pregnant women presenting in <strong>active labour</strong> and <strong>breastfeeding women</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Abacavir + Lamivudine + Efavirenz</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li aria-level=\"1\">All PLHIV with <strong>abnormal serum creatinine</strong> values&nbsp;</li>\n<li aria-level=\"1\">All PLHIV with <strong>bodyweight less &lt;30 kg</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td class=\"td1\" valign=\"top\">\n<p class=\"p1\">Tenofovir + Lamivudine + Efavirenz /Lopinavir /Ritonavir</p>\n</td>\n<td class=\"td1\" valign=\"top\">\n<ul>\n<li>Women of childbearing age group who do not wish to take Dolutegravir</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li class=\"p1\">All PLHIV who were on the previous recommended regime&nbsp;(Tenofovir+Lamivudine+Efavirenz) to be counselled to switch to new regime. Continue older regime if response is good</li>\n<li class=\"p1\">Women in child-bearing age group to be counselled about Dolutegravir with opt-out option before switching to new regime</li>\n</ul>\n<p>*PLHIV: People living with HIV</p><hr><h3>Related Pearl: Prevention of parent to child transmission (PPTCT)</h3><p>Important provisions of PPTCT services for HIV:</p>\n<ul>\n<li>HIV counseling and testing for all pregnant women enrolled in antenatal care with &lsquo;opt out&rsquo; option.</li>\n<li>Lifelong ART i.e. <strong>Tenofovir (TDF) + Lamivudine (3TC)+ Dolutegravir (DTG)</strong> administration to all pregnant and breastfeeding HIV-infected women <strong>regardless of CD4 count and clinical stage</strong>.</li>\n<li>Institutional deliveries of HIV-infected mothers</li>\n<li>Care of associated conditions (STI/RTI, TB, opportunistic infections, hypertension, diabetes)</li>\n<li>Exclusive breastfeeding counseling</li>\n<li><strong>Plasma viral load testing</strong> at <strong>32&ndash;36 weeks of gestation</strong> to determine the risk of HIV transmission to the baby</li>\n<li aria-level=\"1\">Initiation of ARV in babies:<br />\n<ul>\n<li aria-level=\"2\">Low-risk infants: <strong>Syrup Nevirapine</strong> from <strong>birth till 6 weeks</strong> of age</li>\n<li aria-level=\"2\">High-risk infants: <strong>Syrup Nevirapine+ syrup Zidovudine</strong> either from <strong>birth till 6 weeks</strong> of age (exclusive replacement feeding) or from <strong>birth till 12 weeks</strong> of age (exclusive breastfeeding)</li>\n</ul>\n</li>\n<li>Nutrition counseling and psychosocial support to HIV-infected pregnant women</li>\n<li>Ensure <strong>co-trimoxazole prophylactic therapy (CPT)</strong> and early infant diagnosis using HIV-DNA PCR at 6 weeks of age onwards as per guidelines</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4478",
      "difficulty": "medium"
    },
    {
      "text": "A newly diagnosed HIV patient presented with fever, cough, and hemoptysis. His sputum sample showed acid-fast bacilli. What is the appropriate management for this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Start ART if CD4<200"
        },
        {
          "id": 2,
          "text": "Start ART and then ATT after 2 weeks"
        },
        {
          "id": 3,
          "text": "Start ATT and then ART after 2 weeks"
        },
        {
          "id": 4,
          "text": "Start ATT and ART simultaneously"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In a patient with HIV and TB <strong>start</strong> <strong>ATT first</strong> and <strong>then start ART</strong> as soon as ATT is tolerated (between <strong>2 weeks</strong> and 2 months) by the patient. This is done in order to avoid immune reconstitution inflammatory syndrome&nbsp;<strong>(IRIS)</strong>.&nbsp;</p>\n<p><strong>Immune Reconstitution Inflammatory Syndrome</strong> <strong>(IRIS):</strong></p>\n<p>Patients with HIV-related TB may experience a temporary <strong>paradoxical exacerbation</strong> of symptoms and radiographic manifestations of TB after starting ATT. This occurs as a result of <strong>immune reconstitution</strong> due to <strong>simultaneous</strong> administration of <strong>ART and ATT</strong>.</p>\n<p>It is characterized by high fever, lymphadenopathy, expanding intra-thoracic lesions, and worsening of chest X-ray findings. Diagnosis should be made only after ruling out treatment failure and other infections. For severe cases, <strong>prednisone</strong> 1-2mg/kg is used for 1-2 weeks and then gradually tapered.</p>\n<p>However, in patients with <strong>CD4 &lt;50/&mu;L,</strong> the benefits of administering ART immediately after initiating ATT outweigh the risks of IRIS, and therefore <strong>ART</strong> should be <strong>started</strong> as<strong> early </strong>as possible.</p>\n<p>Note: As per RNTCP guidelines, <strong>CBNAAT</strong> is the <strong>preferred</strong> diagnostic technique for testing <strong>TB in PLHIV&nbsp;</strong>(people living with HIV). Smear microscopy has poor sensitivity in detecting TB in PLHIV due to fewer organisms in sputum, and hence is not preferred.</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;World HIV day is observed anually on 1st December. This year&rsquo;s theme is &ldquo;Putting Ourselves to the Test: Achieving Equity to End HIV.&rdquo; It encourages people to unite globally to eliminate the disparities and inequities that create barriers to HIV testing, prevention, and access to HIV care&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">World HIV day is observed annually on 1st December. This year&rsquo;s theme is &ldquo;Putting Ourselves to the Test: Achieving Equity to End HIV.&rdquo; It encourages people to unite globally to eliminate the disparities and inequities that create barriers to HIV testing, prevention, and access to HIV care</span></p><hr><h3>Related Pearl: Opportunistic Infections/HIV related conditions and ART initiation</h3><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action&nbsp;</td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia)&nbsp;</td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems)&nbsp;</td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment&nbsp;</td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF5957",
      "difficulty": "easy"
    },
    {
      "text": "What is the diagnostic test of choice for HIV in a baby born to an HIV-infected mother?",
      "choices": [
        {
          "id": 1,
          "text": "HIV DNA PCR"
        },
        {
          "id": 2,
          "text": "Cord blood ELISA"
        },
        {
          "id": 3,
          "text": "Western blot"
        },
        {
          "id": 4,
          "text": "Third generation ELISA"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In a <strong>baby</strong> born to an <strong>HIV-infected mother</strong>, HIV infection is diagnosed using <strong>HIV DNA PCR</strong>. NACO recommends the use of a qualitative HIV-1 DNA PCR (NAT) in children aged &lt;18 months for <strong>Early Infant Diagnosis&nbsp;</strong>(EID).</p>\n<p><strong>Antibody assays</strong> (e.g., ELISA) are <strong>not reliable</strong> in infants and young children because of the persistence of transplacentally acquired maternal antibodies. For this reason, HIV virologic testing must be performed using tests that detect HIV DNA or RNA to diagnose HIV infection in children.</p>\n<p><strong>Scheduled repeated testing</strong> is necessary because test sensitivity increases with time from HIV virus exposure and very recent infection will not be detectable. The <strong>cord blood</strong> should <strong>not be used</strong> for testing because of the possibility of contamination of the sample with maternal blood.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2161",
      "difficulty": "medium"
    },
    {
      "text": "A 29-year-old HIV-positive woman presents to the OPD with fever, cough, and hemoptysis. Chest X-ray is given below. What is the diagnostic test for this condition in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Cartridge based nucleic acid amiplification test"
        },
        {
          "id": 2,
          "text": "Sputum microscopy & AFB staining"
        },
        {
          "id": 3,
          "text": "Interferon gamma release assay"
        },
        {
          "id": 4,
          "text": "Bronchoalveolar lavage fluid cytology"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of <strong>tuberculosis</strong>.&nbsp;Cartridge-based nucleic acid amiplification test (<strong>CBNAAT</strong>) is the diagnostic test for <strong>TB in HIV&nbsp;</strong>positive patients.&nbsp;</p>\n<p class=\"p1\">CBNAAT is a <strong>rapid</strong> molecular test that detects the <strong>DNA </strong>of TB bacteria in HIV-positive individuals. It uses sputum or any other biological specimen (except blood and blood-contaminated specimens). It can give a result in less than 2 hours. It can also detect the genetic <strong>mutations</strong> associated with <strong>resistance</strong> to the drug <strong>rifampicin</strong>.&nbsp;</p>\n<p>Sputum microscopy has poor sensitivity for detecting TB in HIV-infected individuals due to fewer organisms in sputum.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/99cd01362b8443a688d701311b3d05c4.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2172",
      "difficulty": "medium"
    },
    {
      "text": "A 52-year-old man was admitted for multiple episodes of seizures following 7 months of neurocognitive decline. He also had weight loss, paranoia, and delusions. Clinical workup revealed HIV infection along with the following findings on MRI. What is the ideal timing of steroid therapy in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "1 day before performing a biopsy"
        },
        {
          "id": 2,
          "text": "Just before obtaining the sample for a biopsy"
        },
        {
          "id": 3,
          "text": "Only after obtaining a biopsy"
        },
        {
          "id": 4,
          "text": "There is no specific ideal timing"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of <strong>primary CNS lymphoma&nbsp;</strong>(PCNSL). In this condition, <strong>glucocorticoids</strong> should be administered only <strong>after </strong>a<strong> biopsy</strong> has been obtained. This is because steroids have a<strong> cytolytic effect </strong>on lymphoma cells and hence may lead to nondiagnostic tissue. &nbsp;</p>\n<p>On CT, PCNSL is identified as a hyperdense enhancing supratentorial mass. On MRI, vivid homogeneous enhancement, as well as restricted diffusion, is seen.&nbsp;</p>\n<p>PCNSL is a type of&nbsp;<strong>non-Hodgkin's lymphoma</strong>. The workup usually includes:</p>\n<ul>\n<li>HIV testing</li>\n<li>CSF analysis</li>\n<li>MRI spine&nbsp;</li>\n<li>PET/CT to assess the extent of the disease</li>\n<li>Bone marrow biopsy</li>\n</ul><p>World AIDS Vaccine Day, also known as <strong>HIV Vaccine Awareness Day</strong>, is observed annually on <strong>May 18</strong>. HIV vaccine advocates mark the day by promoting the continued urgent need for a vaccine to prevent HIV infection and AIDS.</p><hr><h3>Related Pearl: AIDS-defining opportunistic infections and neoplasm</h3><p><strong>Infections:</strong></p>\n<ul>\n<li><strong>Protozoal and helminthic infections-</strong>\n<ul>\n<li>Cryptosporidiosis or Isosporiasis (cystoisosporiasis) - Chronic intestinal</li>\n<li>Toxoplasmosis (pneumonia or CNS infection)</li>\n</ul>\n</li>\n<li><strong>Fungal infections-</strong>\n<ul>\n<li>Candidiasis (esophageal, tracheal, or pulmonary)</li>\n<li>Cryptococcosis (CNS infection)</li>\n<li>Coccidioidomycosis (disseminated)</li>\n<li>Pneumocystosis (pneumonia or disseminated infection)</li>\n<li>Histoplasmosis (disseminated)</li>\n</ul>\n</li>\n<li><strong>Bacterial infections-</strong>\n<ul>\n<li>Mycobacteriosis (&ldquo;atypical,&rdquo; e.g., <em>Mycobacterium avium-intracellulare</em>)&nbsp;disseminated or extrapulmonary</li>\n<li>Mycobacterium tuberculosis (pulmonary&nbsp;or extrapulmonary)</li>\n<li>Nocardiosis (pneumonia, meningitis, disseminated)</li>\n<li>Salmonella infections, disseminated</li>\n</ul>\n</li>\n<li><strong>Viral infections-</strong>\n<ul>\n<li>Cytomegalovirus (pulmonary, intestinal, retinitis, or CNS infections)</li>\n<li>Herpes simplex virus (localized or disseminated infection)</li>\n<li>Varicella-zoster virus (localized or disseminated infection)</li>\n<li>Progressive multifocal leukoencephalopathy</li>\n</ul>\n</li>\n</ul>\n<p><strong>Neoplasms:</strong></p>\n<ul>\n<li>Kaposi sarcoma</li>\n<li>Primary lymphoma of brain</li>\n<li>Invasive cancer of uterine cervix&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/35488a35aa56417d9fdf10ff17c6a1e0.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6358",
      "difficulty": "medium"
    },
    {
      "text": "What is the WHO recommendation regarding the initiation of cotrimoxazole prophylaxis?",
      "choices": [
        {
          "id": 1,
          "text": "Any CD4 count or WHO clinical stage"
        },
        {
          "id": 2,
          "text": "CD4 count <500 and/or WHO stage 3/4"
        },
        {
          "id": 3,
          "text": "CD4 count <350 and/or WHO stage 3/4"
        },
        {
          "id": 4,
          "text": "CD4 count <150 and/or WHO stage 3/4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>WHO recommends cotrimoxazole prophylaxis at <strong>CD4 count &lt;350 and/or WHO stage 3/4</strong>.</p>\n<p>Only in settings where <strong>malaria or severe bacterial infections</strong> are highly prevalent, co-trimoxazole prophylaxis should be initiated regardless of WHO clinical stage or CD4 counts.</p>\n<p>Prophylaxis in HIV patients:</p>\n<div class=\"page\" title=\"Page 1476\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<table>\n<tbody>\n<tr>\n<td><strong>Organism</strong></td>\n<td><strong>CD4 count below which prophylaxis is started</strong></td>\n<td><strong>Drug given</strong></td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 1477\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Pneumocystis jirovecii</p>\n</div>\n</div>\n</div>\n</td>\n<td>\n<p>&lt;200/mm<sup>3</sup></p>\n<p><sup>&nbsp;</sup>(Acc to CDC)</p>\n<p>&lt;350 /mm<sup>3</sup></p>\n<p>(Acc to WHO and NACO)</p>\n</td>\n<td>TMP-SMX (Cotrimoxazole)</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 1477\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mycobacterium-avium complex</p>\n</div>\n</div>\n</div>\n</td>\n<td>&lt;50/mm<sup>3</sup></td>\n<td>Azithromycin</td>\n</tr>\n<tr>\n<td>\n<div class=\"page\" title=\"Page 1477\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Toxoplasma gondii</p>\n</div>\n</div>\n</div>\n</td>\n<td>&lt;100/mm<sup>3</sup></td>\n<td>TMP-SMX (Cotrimoxazole)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n</div>\n</div>\n</div><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;FDA recently approved Cabotegravir extended-release injectable suspension for use in at-risk adults &amp; adolescents for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV. It is given first as two initiation injections administered one month apart and then every two months after that. &quot;}\" data-sheets-userformat=\"{&quot;2&quot;:33563519,&quot;3&quot;:{&quot;1&quot;:0},&quot;4&quot;:{&quot;1&quot;:2,&quot;2&quot;:6989903},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0,&quot;16&quot;:10,&quot;28&quot;:1}\">FDA recently approved <strong>Cabotegravir extended-release</strong> <strong>injectable suspension</strong> for use in at-risk adults &amp; adolescents for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV. It is given first as two initiation injections administered one month apart and then every two months after that. </span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2165",
      "difficulty": "medium"
    },
    {
      "text": "A cachexic man presented with a non-productive cough and shortness of breath. He was diagnosed with HIV 6 months ago but is non-adherent to ART. Serum LDH is 350 U/L. Giemsa-stained smears are seen below. At what CD4 count should the prophylaxis be started according to the CDC recommendation to prevent this disease?<div class='question-desc-html'><p> </p>\n<p> </p></div>",
      "choices": [
        {
          "id": 1,
          "text": "<100/mm3"
        },
        {
          "id": 2,
          "text": "<150/mm3"
        },
        {
          "id": 3,
          "text": "<400/mm3"
        },
        {
          "id": 4,
          "text": "<200/mm3"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\">The given clinical scenario is suggestive of <strong>p</strong><span data-preserver-spaces=\"true\"><strong>neumocystis pneumonia (PCP)<em>.</em></strong> The p</span>rophylaxis for PCP is started at<strong><span data-preserver-spaces=\"true\"> &lt;200/mm<sup>3</sup> CD4 count</span></strong> according to the CDC recommendation.<strong> </strong>In PCP <strong>LDH is elevated</strong> and <span data-preserver-spaces=\"true\">smear stained with Giemsa stain shows <strong>trophic forms</strong> with <strong>dot-like nuclei</strong> and pale blue cytoplasm as well as intracystic bodies of <strong><em>Pneumocystis jiroveci.</em></strong></span></p>\n<p>Primary prophylaxis of PCP:</p>\n<table>\n<tbody>\n<tr>\n<td>Indications</td>\n<td>\n<ul>\n<li>CD4+ T cell count &lt;200/uL ( CD4 cell %&lt;15)</li>\n<li>Recent oropharyngeal candidiasis and prior PCP</li>\n</ul>\n<ul>\n<li>Any patient with unexplained fever for &gt; 2 weeks.</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Drug of choice</td>\n<td>\n<p><strong>Trimethoprim/sulfamethoxazole </strong>(TMP/SMX), one double-strength tablet daily. </p>\n<p>Alternatives- Dapsone/Pyrimethamine + Leucovorin or Atovaqone or Aerosolised Pentamidine</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Note : TMP-SMX also provides protection against toxoplasmosis and some bacterial respiratory pathogens. The prophylaxis is discontinued in those patients treated with ART who maintain good suppression of HIV (&lt;50 copies/mL) and CD4+ T-cell counts &gt;200/ μL for at least 3 months.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e4519552dd7c43a9b4fdd6cbe7bc3642.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "ME6072",
      "difficulty": "medium"
    },
    {
      "text": "You suffer a bleeding puncture wound on your finger while assisting with surgery on a patient infected with HIV. What regimen should you take in this situation?",
      "choices": [
        {
          "id": 1,
          "text": "Zidovudine + Lamivudine for 4 weeks"
        },
        {
          "id": 2,
          "text": "Lamivudine + Tenofovir + Efavirenz for 4 weeks"
        },
        {
          "id": 3,
          "text": "Lamivudine + Tenofovir + Dolutegravir for 4 weeks"
        },
        {
          "id": 4,
          "text": "Tenofovir + Lamivudine + Nevirapine for 4 weeks"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Recommended <strong>post-exposure prophylaxis&nbsp;</strong>(PEP) is a three-drug regimen that includes<strong>&nbsp;lamivudine,&nbsp;</strong><strong>tenofovir, and dolutegravir</strong>.</p>\n<p>A regimen for HIV post-exposure prophylaxis with two ARV drugs is effective, but three drugs are preferred. The PEP must be initiated <strong>ideally within 2 hours</strong> and certainly <strong>within 72 hours</strong>.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/8115059da00d45c195c82188db4e14ccx1280x1488.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: 2021 NACO Guidelines on Post-exposure Prophylaxis (PEP) for HIV</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Exposure Code</strong></p>\n</td>\n<td>\n<p><strong>HIV Source Code</strong></p>\n</td>\n<td>\n<p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; PEP Recommendation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Not required</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;1</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>\n<p>&nbsp;2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>\n<p>&nbsp;1/2</p>\n</td>\n<td>\n<p>&nbsp;Recommended</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>2/3</p>\n</td>\n<td>\n<p>Not known</p>\n</td>\n<td>\n<p>Consider PEP if HIV prevalence is high in the given population</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Exposure Codes</strong></p>\n<ul>\n<li>EC1: <strong>Mild exposure:</strong> mucous membrane/non-intact skin with small volumes/eyes or mucous membrane or subcutaneous injections following small-bore needles</li>\n<li>EC2:&nbsp;<strong>Moderate exposure: </strong>mucous membrane/non-intact skin with large volumes or percutaneous superficial exposure with a solid needle</li>\n<li>EC3:&nbsp;<strong>Severe exposure: </strong>percutaneous with large volume by hollow needle, deep puncture</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>HIV Source Codes</strong></p>\n<ul>\n<li>SC 1- HIV +ve, asymptomatic, CD count high, low viral load</li>\n<li>SC 2- HIV +ve, symptomatic, CD count low, high viral load</li>\n<li>SC unknown: HIV status unknown</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p><strong>Recommended PEP regimens</strong></p>\n<p>1) <strong>Adolescents and Adults</strong> (&gt;10 years of age and &gt;30 kg weight): Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg</p>\n<p>2) <strong>Children&nbsp;</strong>(&gt;6 years of age and &gt;20 kg weight): Zidovudine&nbsp;(dosage as per weight band) + Lamivudine (dosage as per weight band) + Dolutegravir 50 mg</p>\n<ul>\n<li aria-level=\"1\">PEP must be initiated ideally <strong>within 2 hours</strong> and certainly within 72 hours.</li>\n<li aria-level=\"1\">Duration of PEP: <strong>28 days/4weeks</strong></li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC2166",
      "difficulty": "medium"
    }
  ]
}